ABC | Volume 112, Nº3, Março 2019

Artigo de Revisão Jorge et al Imagem na disfunção ventricular por quimioterapia Arq Bras Cardiol. 2019; 112(3):309-316 1. Brasil. Ministério da Saúde. Dados de Taxa deMortalidade Específica (TME). DATASUS 2008/2009 disponível em http://tabnet.datasus.gov.br/cgi/tabcgi. exe?idb2009/c10.def. Acesso em 20/01/2011 2. Martins WA, Moço ETSM. Cardio-oncologia: o preço do envelhecimento. Rev Bras Cardiol.2012;25(3):164-6. 3. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al . Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation.2004;109(25):3122-31. 4. Cardinale D, Colombo A, Torrisi R, Sandri MT , Civelli M, Salvatici M, et al . Trastuzumab-induced cardiotoxicity: Clinical and prognostic implications of troponin I evaluation. J Clin Oncol.2010;28(25):3910-6. 5. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol.2005; 23:8597-605. 6. Armstrong GT , Oeffinger KC, Chen Y, Kawashima T , Yasui Y , LeisenringW , et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol.2013;31(29):3673-80. 7. Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP , Sami A, et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol.2013;14:72-80. 8. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr.2014;27(9):911-39. 9. Zamorano JL, Lancellotti P, Munoz DR, Aboyans V, Asteggiano R, Galderisi M, et al . 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail.2017;19:9-42. 10. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al . Cardiac Dysfunction intheTrastuzumabClinicalTrialsExperience.JClinOncol.2002; 20:1215-21. 11. Douglas OS, Garcia MJ, Haines DE, Lai WW, Manning WJ, Patel AR, et al . ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/ SCCT/ SCMR 2011 Appropriate Use Criteria for Echocardiography. J Am Soc Echocardiogr.2011;24:229-67. 12. ThavendiranathanP,GrantAD,NegishiT,PlanaJC,Popovic´ZB,MarwickTH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J AmColl Cardiol. 2013;61:77-84. 13. Paraskevaidis IA, Makavos G, Tsirigotis P, Psarogiannakopoulos P, Parissis J, Gkirkas K, et al. Deformation Analysis of Myocardial Layers Detects Early Cardiac Dysfunction after Chemotherapy in Bone Marrow Transplantation Patients: A Continuous and Additive Cardiotoxicity Process. J Am Soc Echocardiogr. 2017;30(11):1091-102. 14. Dorup I, Levitt G, Sullivan I, Sorensen K. Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function.2004. Heart. 2004;90(10):1214-6. 15. Pellicori P, Calicchia A, Lococo F, Cimino G, Torromeo C. Subclinical anthracycline cardiotoxicity in patients with acute promyelocytic leucemia in long-termremissionaftertheAIDAprotocol.CongHeartFail.2012;18:217-21. 16. Serrano JM, Gonzalez I, Del Castillo S, Muniz J, Morales LJ, Moreno F, et al. Diastolic Dysfunction Following Anthracycline-Based Chemotherapy in Breast Cancer Patients: Incidence and Predictors. The Oncologist. 2015;20:864-72. 17. Stoodley PW, Richards DAB, Hui R, Boyd A, Harnett PR, Meikle SR, et al. Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. Euro J Echocardiogr. 2011;12:945-52. 18. Barendswaard EC, Prpi H, Van der Wall EE, Camps JA, Keizer HJ, Pauwels EK. Right ventricule wall motion abnormalities in patients treated with chemotherapy. Clin Nucl Med.1991;16(7):513-6. 19. Lang RM, Badano LP, MD, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al . Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1-39. 20. Jenkins C, Moir S, Chan J, Rakhit D, Haluska B, and Marwick TH. Left ventricular volume measurement with echocardiography: a comparison of left ventricular opacification, three-dimensional echocardiography, or both with magnetic resonance imaging. Eur Heart J. 2009;30(1):98-106. 21. Muraru D, Badano LP, Piccoli G, Gianfagna P, Del Mestre L, Ermacora D, et al. Validation of a novel automated border-detection algorithm for rapid and accurate quantitation of left ventricular volumes based on three-dimensional echocardiography. Eur J Echocardiogr. 2010;11(4):359-68. 22. Dorosz JL,LezotteDC,WeitzenkampDA,AllenLA,SalcedoEE. Performance of 3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction: a systematic review and meta-analysis. J Am Coll Cardiol. 2012;59(20):1799-808. 23. Walker J, Bhullar N, Fallah-Rad N, Lytwyn M, Golian M, Fang T , et al . Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol. 2010;28(21):3429-36. 24. Hoffmann R, Bardeleben S, Cate F, Borges AC, Kasprzak J, Firschke C, et al. Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiacmagnetic resonance imaging, unenhanced and contrast-enhanced echocardiography. Eur Heart J. 2005;26:607-16. 25. Farsalinos KE, Daraban AM, Unlu S, Thomas JD, Badano LP, Voigt JU. Head- to-Head Comparison of Global Longitudinal Strain Measurements among Nine Different Vendors The EACVI/ASE Inter-Vendor Comparison Study. J Am Soc Echocardiogr. 2015;28:1171-81. 26. Stanton T, Leano R, Marwick TH. Prediction of All-Cause Mortality From Global Longitudinal Speckle Strain ComparisonWith Ejection Fraction and Wall Motion Scoring. Circ Cardiovasc Imaging.2009;2:356-364. 27. Charbonnel C, Convers-Domart R, Rigaudeau S, Taksin AL, Baron N, Lambert J, et al. Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity.Eur Heart J Cardiovasc Imaging 2017;18:392-401. 28. Mousavi N, Tan TC, Ali M, Halpern EF, Wang L, Scherrer-Crosbie M. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines. Eur Heart J Cardiovasc Imaging. 2015;16:977–84. 29. Kang Y, Xu X, Cheng L, Li L, SunM, Chen H, et al . Two-dimensional speckle tracking echocardiography combinedwith high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy. Eur J Heart Fail. 2014;16:300-8. 30. SawaiaH, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V , et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107(9):1375-80. 31. Sawaia H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes and traztuzumab. Circ Cardiovasc Imaging. 2012;5(5):596-603. 32. NegishiK,NegishiT,HareJL,HaluskaBA,PlanaJC,MarwickTH.Independent andIncrementalValueofDeformationIndicesforPredictionofTrastuzumab- Induced Cardiotoxicity. J Am Soc Echocardiogr. 2013;26:493-8. Referências 315